Review: Combined Candesartan Cilexetil and Pioglitazone Hydrochloride therapy in Metabolic Syndrome

  • Posted on: 31 May 2016
  • By: admin

 

Magazine Home


June 2016 ARTICLE LIST >>

PharmaTutor (June- 2016)

 

Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 6)

 

Received On: 20/01/2016; Accepted On: 27/01/2016; Published On: 01/06/2016

 

AUTHORS:
Chauhan Sudhanshu*1,2, Savani Pankaj2, Solanki Divya2, Raj Hasumati2, Patel Sagar2
1Research Scholar, Gujarat Technological University, Ahmedabad, Gujarat, India
2Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim, Surat, Gujarat, India
* sudhanshuchauhan32@yahoo.com

 

ABSTRACT: This review article presents the pharmacology of combined Candesartan Cilexetil and Pioglitazone Hydrochloride therapy specially in Metabolic syndrome. Candesartan Cilexetil is a antihypertensive agent. Pioglitazone Hydrochloride is a selectively stimulates nuclear receptor peroxisome proliferator activated receptor gamma (PPAR-gamma). The use of Candesartan Cilexetil in combination with Pioglitazone Hydrochloride has been proved to provide beneficial effect (Synergistic effect) in metabolic syndrome. The mechanism of Candesartan Cilexetil and Pioglitazone Hydrochloride is quite different. The combination of both also have anti inflammatory and enhanced organ protective effects. The main objective of this review article is to provide pharmacological information of combined therapy of Candesartan Cilexetil and Pioglitazone Hydrochloride to researcher in development of combined dosage form of this combination.

 

How to cite this article: Chauhan S, Savani P, Solanki D, Raj H, Patel S; Review: Combined Candesartan Cilexetil and Pioglitazone Hydrochloride therapy in Metabolic Syndrome; PharmaTutor; 2016; 4(6); 23-28

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML